CRISPR Therapeutics AG
DE ˙ DB
50,00 € ↑6,00 (13,64%)
2026-06-04
CENA AKCJI
SecurityDE:1CG / CRISPR Therapeutics AG
InstitutionState Street Corp
Latest Disclosed Ownership3,982,500 shares
Latest Disclosed Value $ 189,447,525
State Street Corp reports 6.10% increase in ownership of 1CG / CRISPR Therapeutics AG

On May 15, 2026 - State Street Corp filed a 13F-HR form disclosing ownership of 3,982,500 shares of CRISPR Therapeutics AG (DE:1CG) valued at $155,317,500 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 3,753,440 shares of CRISPR Therapeutics AG. This represents a change in shares of 6.10% during the quarter. The current value of the position is $199,125,000 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 3,982,500 229,060 6.10 189,448 -3.75 0.0065
2026-02-13 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 3,753,440 -253,793 -6.33 196,830 -24.21 0.0066
2025-11-14 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 4,007,233 736,637 22.52 259,709 63.26 0.0090
2025-08-14 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 3,270,596 859,334 35.64 159,082 93.87 0.0060
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,411,262 -80,263 -3.22 82,055 -16.33 0.0034
2025-02-14 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,491,525 -501,463 -16.75 98,066 -30.26 0.0039
2024-11-14 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,992,988 599,304 25.04 140,611 8.76 0.0057
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,393,684 898,476 60.09 129,283 26.86 0.0056
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,495,208 -258,289 -14.73 101,913 -7.16 0.0046
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,753,497 -131,476 -6.97 109,769 28.30 0.0053
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,884,973 252,500 15.47 85,559 -6.64 0.0047
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,632,473 -353,714 -17.81 91,647 2.02 0.0048
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,986,187 -94,929 -4.56 89,833 6.19 0.0051
2023-05-15 2022-12-31 13F/A-99 CRISPR THERAPEUTICS NAMEN AKT H17182108 2,081,116 512,732 32.69 84,597 -17.46 0.0050
2023-05-15 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,081,116 512,732 84,597 0.0050
2022-11-15 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,568,384 -1,476 -0.09 102,494 7.44 0.0065
2022-08-15 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,569,860 1,092,384 228.78 95,400 218.31 0.0057
2022-05-16 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 477,476 269,824 129.94 29,971 90.46 0.0015
2022-02-14 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 207,652 45,010 27.67 15,736 -13.56 0.0007
2021-11-15 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 162,642 11,726 7.77 18,205 -25.49 0.0010
2021-08-16 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 150,916 1,661 1.11 24,432 34.34 0.0013
2021-07-09 2021-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 149,255 13,894 10.26 18,187 -12.25 0.0010
2021-05-17 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 142,189 6,828 17,326 0.0010
2021-02-16 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 135,361 -5,950 -4.21 20,725 75.35 0.0013
2020-11-10 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 141,311 20,522 16.99 11,819 33.14 0.0008
2020-08-14 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 120,789 49,578 69.62 8,877 193.94 0.0006
2020-06-19 2020-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 71,211 23,159 48.20 3,020 3.18 0.0003
2020-05-11 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 71,211 3,020
2020-02-06 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 48,052 10,949 29.51 2,927 92.44 0.0002
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 37,103 758 2.09 1,521 -11.16 0.0001
2019-08-14 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 36,345 10,292 39.50 1,712 83.89 0.0001
2019-05-15 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 26,053 -300 -1.14 931 23.64 0.0001
2019-02-12 2018-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 26,353 -1,117 -4.07 753 -38.23 0.0001
2018-11-09 2018-09-30 13F CRISPR THERAPEUTICS Common equity shares H17182108 27,470 3,337 13.83 1,219 -14.03 0.0001
2018-08-14 2018-06-30 13F CRISPR THERAPEUTICS Common equity shares H17182108 24,133 24,133 1,418 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.